UK Multivitamin Corrects Key Nutrient Deficiencies; Prompts Call for Guideline Review
A UK-based clinical trial demonstrates a multivitamin's efficacy in correcting widespread micronutrient deficiencies, revealing significant prevalence in ostensibly healthy adults and prompting calls for a review of national dietary guidelines.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 16 April 2026
A recent clinical trial in the UK, conducted by Heights in collaboration with King’s College London and the Functional Gut Clinic, has unveiled significant micronutrient deficiencies among ostensibly healthy adults, challenging existing notions of nutritional adequacy. The study, presented at the Nutrition Society Conference by Dr. Harry Jarrett, Heights' Director of Science and Research, indicated that 40% of participants were folate deficient, 34% lacked active B12, and 83% had suboptimal or deficient riboflavin status at baseline. These findings, consistent with prior research showing a 50% riboflavin deficiency rate in UK adults and a 3% annual decline in red blood cell folate over two decades, underscore a pressing public health concern.
The 12-week intervention involved 35 healthy adults, randomised to receive either Heights’ Vitals multivitamin or a placebo. The active group demonstrated substantial improvements in key biomarkers. All elevated homocysteine levels were corrected, while red blood cell folate increased by 82%, active B12 by 25%, vitamin B6 by 115%, and riboflavin by 17%. Dr. Jarrett attributed these results to the multivitamin’s deliberate formulation, incorporating optimal doses, biologically active nutrient forms, and synergistic nutrient interactions, particularly for B-vitamins crucial for one-carbon metabolism. For instance, the use of 5-MTHF folate accommodates the 12% of the UK population with the MTHFR enzyme issue, which impairs folic acid conversion.
The research suggests that the efficacy of supplements relies heavily on product formulation, including the form, dose, and synergistic combination of nutrients. Dr. Jarrett emphasised that merely including a nutrient on a label does not guarantee biological activity or efficacy, a critical distinction for the industry. He highlighted that current UK Reference Nutrient Intakes, designed to prevent clinical deficiencies rather than ensure optimal status, are outdated given contemporary dietary patterns and widespread consumption of ultra-processed foods.
While acknowledging the positive impact of national fortification initiatives, such as the upcoming mandatory folic acid fortification of flour, Dr. Jarrett argued these measures are insufficient. He advocates for a broader, evidence-driven review of which nutrients the UK population lacks and a willingness to implement multi-nutrient interventions, including supplementation, to address the pervasive issue of 'hidden' micronutrient deficiencies effectively.
What this means for United Kingdom
UK brand owners must acknowledge the high prevalence of 'hidden' micronutrient deficiencies, driving demand for advanced multivitamin formulations. Products incorporating active nutrient forms like 5-MTHF folate (over folic acid) and methylcobalamin B12 will gain a competitive edge, aligning with consumer demand for efficacy and addressing specific genetic variations. Regulatory scrutiny around substantiating efficacy claims will intensify, requiring manufacturers to invest in clinical data or robust scientific backing. Opportunities exist for brands to lead in educating consumers on optimal nutrient forms and synergistic formulations, differentiating themselves in a crowded market. Procurement leads should assess supplier capabilities for these premium ingredient forms to secure supply and maintain compliance with evolving scientific understanding.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.